Announcement 10.31.23 Share on Twitter Share on Facebook Share on LinkedIn PICI Network Researchers to Present at 2023 Annual Meeting of Society for Immunotherapy of Cancer #SITC23 21 members of the Parker Institute for Cancer Immunotherapy (PICI) Network will present at the 38th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC), Nov. 1-5 in San Diego, California. The conference aims to provide a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy. Robert Schreiber, PhD, of Washington University School of Medicine in St. Louis, will receive the Richard V. Smalley Memorial Award & present a primary keynote as part of the award. Established in 2005, the SITC Smalley Award is the society’s most prestigious award and serves to honor those who have been pioneers in their work and made a notable impact worthy of high regard and recognition by their peers. Featured current and former PICI Network members (in order of their presentations) are: Robert D. Schreiber, PhD – Washington University School of Medicine Lewis L. Lanier, PhD – University of California, San Francisco Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center Beatriz M. Carreno, PhD – University of Pennsylvania Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center Catherine J. Wu, MD – Dana-Farber Cancer Institute Dorota Klysz, PhD – Stanford University School of Medicine Crystal L. Mackall, MD – Stanford University Lili Yang, PhD – University of California, Los Angeles Marco Ruella, MD – University of Pennsylvania Taha Merghoub, PhD – Weill Cornell Medicine Matthew Brown, MS, BA – Icahn School of Medicine at Mount Sinai Carl June, MD, FAIO – University of Pennsylvania Yvonne Chen, PhD – University of California, Los Angeles Judith Agudo, PhD – Dana-Farber Cancer Institute Bridget P. Keenan, MD, PhD – University of California, San Francisco Robert Prins, PhD – University of California, Los Angeles Hideo Okada, MD, PhD – University of California, San Francisco Christine Brown, PhD – City of Hope Kole Roybal, PhD – University of California, San Francisco Below is information related to the schedule of presentations of PICI Network members. A full schedule can be viewed here. Thursday, Nov. 2, 2023 | Pre-Conference Programs Primer on Tumor Immunology and Cancer Immunotherapy™ | 8 a.m.–10:30 p.m. PDT Program Co-Organizer: Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center Session I: The Cancer Immunity Cycle 8:15 a.m. Adaptive Immune Responses to Cancer (Presenter: Robert D. Schreiber, PhD – Washington University School of Medicine) 9:15 a.m. Innate Lymphocytes and Natural Killer Cells in Cancer Immunity (Presenter: Lewis L. Lanier, PhD – University of California, San Francisco) Session III: Driving T Cells to the Tumor 1:40 p.m. Introduction (Co-Chair: Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center) 1:45 p.m. Vaccines as Initiators of the Cancer-Immunity Cycle (Presenter: Beatriz M. Carreno, PhD – University of Pennsylvania) 2:10 p.m. Immune Checkpoint Therapy in Cancer (Presenter: Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center) 3 p.m. Modulating the Tumor Microenvironment with T Cell Bispecifics (Presenter: Sumit K. Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center) Session IV: Influencers of the Response to Immunotherapies 3:40 p.m. Immune Checkpoint Therapy: Biomarkers of Response and Resistance (Presenter: Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center) 4:05 p.m. Developing Personalized Cancer Vaccines (Presenter: Catherine J. Wu, MD – Dana-Farber Cancer Institute) Targeting Myeloid Cells in Immuno-Oncology | Thursday, Nov. 2, 2023 | 9 a.m.–5:30 p.m. PDT Session I: Myeloid Cells in Cancer: Recent Advances 10:20 a.m. Unleashing the Antitumor Potential of Neutrophil in the Context of Immune Based Intervention (Presenter: Taha Merghoub, PhD – Weill Cornell Medicine) Friday, Nov. 3, 2023 | Annual Meeting Session 102: Richard V. Smalley Memorial Award and Lectureship | 8:20-9:10 a.m. PDT 8:25 a.m. Cancer Immunoediting: Targets, Mechanisms and Implications for Immunotherapy (Presenter: Robert Schreiber, PhD, FAIO – Washington University School of Medicine) Concurrent Session 105a: Rapid Oral Abstract-Basic Science | 12:15–1:15 p.m. PDT 12:31 p.m. (275) Inosine endows CAR T cells with features of increased stemness and anti-tumor potency (Presenter: Dorota Klysz, PhD – Stanford University School of Medicine) Concurrent Session 105c: Virtual Only Session: Meet an IO Expert | 12:30 pm – 1 p.m. PDT Discussion and Q&A (Co-Chair: Crystal L. Mackall, MD – Stanford University) Concurrent Session 106a: Mechanisms of Resistance to Immune Checkpoint Inhibitors | 1:30–3:10 p.m. PDT 1:40 p.m. Non-T Cell Based Resistance Mechanisms (Presenter: Lili Yang, PhD – University of California, Los Angeles) Concurrent Session 106b: Microbiome and Cancer | 1:30–3:10 p.m. PDT 2.35 p.m. Cell Therapy, Antibiotics, Interventional Trials (Presenter: Marco Ruella, MD – University of Pennsylvania) Concurrent Session 106c: Immunoprevention of Cancer | 1:30–3:10 p.m. PDT Co-Chair: Catherine Wu, MD Dana-Farber Cancer Institute 2:40 p.m (138) Shared frameshift neoantigens are expressed throughout mismatch repair deficient cancer development and are recognized by tissue infiltrating T cells that are dysregulated in advanced lesions (Presenter: Matthew Brown, MS, BA – Icahn School of Medicine at Mount Sinai) Concurrent Session 107b: Promising Novel Biotechnologies for the Next Wave of IO Innovation | 3:30–5:10 p.m. PDT 3:40 p,m. CAR T in Solid Tumor (Presenter: Carl June, MD, FAIO University of Pennsylvania) Saturday, Nov. 4, 2023 | Annual Meeting Session 201: Organizer Welcome 8-8:05 a.m. Chair: Yvonne Chen, PhD University of California, Los Angeles Session 205c: Virtual Only Session: Expert Panel Discussion | 12:30 – 1 p.m. PDT Panel Discussion (Co-Chair: Judith Agudo, PhD – Dana-Farber Cancer Institute) Session 206: Presidential Session | 1:25–2:50 p.m. PDT 2 p.m. Expert discussant: Carl June, MD, FAIO University of Pennsylvania Session 207c: SITC Surgery Committee Session | 3:20–4:45 p.m. PDT 4:25 p.m. (1361) Neoadjuvant CD40 agonism remodels the tumor immune microenvironment in locally advanced esophageal/gastroesophageal junction cancer (Presenter: Bridget P. Keenan, MD, PhD University of California, San Francisco) Session 208a: Neuroimmunology in Cancer | 5:05–6:30 p.m. PDT 5:05 p.m. Introduction (Co-Chair: Robert Prins, PhD University of California-Los Angeles) Session 208a: Neuroimmunology in Cancer | 5:05–6:30 p.m. PDT 5:50 p.m. Novel Strategies to Safely Target Brain Tumor Antigens (Presenter: Hideo Okada, MD, PhD – University of California, San Francisco) Sunday, Nov. 5, 2023 | Annual Meeting Session 302: Thomas Waldmann Memorial Plenary Session: Cell-based Immunotherapies for Treatment of Cancer | 8:20–10:25 a.m. PST Co-Chair: Christine Brown, PhD – City of Hope 8:50 p.m. Towards the Develop of Synthetic Immunity to Cancer (Presenter: Kole Roybal, PhD – University of California, San Francisco) 9:15 a.m. Multi-Pronged CAR-T Cell Therapies for Solid Tumors (Presenter: Yvonne Chen, PhD – University of California, Los Angeles) Session 303: Hot Topic Symposium: Advances in Gene Editing, Synthetic Biology and Designing Innovative Clinical Interventions | 10:40–12:15 p.m. PST Co-Chair: Kole Roybal, PhD – University of California, San Francisco Related Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research Announcement PICI Network Investigators Propel Immunotherapy Progress at SITC 2024 Announcement, Press Release PICI’s 2024 Fall Scientific Retreat Ignites Collaboration to Accelerate Cancer Immunotherapy
Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research
Announcement, Press Release PICI’s 2024 Fall Scientific Retreat Ignites Collaboration to Accelerate Cancer Immunotherapy